Fundraising FoxWren Capital — Full Portfolio
8 tracked investments · listed companies and verified rows first
Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema.
BiotechDigital HealthHealthtechMedical Devices
Olav Hellebø(Chief Executive Officer)in
Co-investorsO2h VenturesWellcome TrustCambridge Angels groupEMV CapitalMartlet CapitalStoic VC+1 more
Keit is a technology hardware company founded in 2013 as a spin-out from the Science and Technology Facilities Council and European Space Agency Business Incubation Centre, developing new technology for established industries.
Advanced ManufacturingDeep TechHardwareOxfordshire, GB
Co-investorsUK Innovation & Science Seed FundFuture Planet CapitalLongwall Venture Partners LLP
Blu Wireless develops millimeter wave radio networking technology for wireless communications.
Deep TechDefense TechHardwareSemiconductorsBristol, GB
Anthony Murray(Chief Executive Officer)inJohnny Bray(Chief Financial Officer)inDave Purle(Chief Operating Officer)Ciara Barron(Director of Marketing)inDarren McNamara(Director of Technology Development)inJonathan Rogers(Director of Systems and Platforms)in
Co-investorsMaven Capital PartnersCambridge Angels groupPerscitus LLPSalica InvestmentsARMCalculus Capital Ltd.+1 more
Bristol-based developer of mmWave wireless communication systems for defence, high-speed rail and other mobility markets.
Co-investorsCalculus Capital Ltd.Guinness VenturesPerscitus LLPARMCalculus
MitoRx develops first-in-class, targeted small-molecule therapies that restore mitochondrial health to treat people with high-risk, metabolically unhealthy obesity and related cardiometabolic diseases.
BiotechHealthtechLongevityHarwell Oxford, GB
Jon R.(Founder)inJon Rees PhD(Co-founder & Chief Executive Officer)Norman Law PhD(Co-founder, Chief Technology Officer & Head of Intellectual Property)
Co-investorsFuture Planet CapitalOxford Investment Opportunity Network (OION)Oxford Technology ManagementUK Innovation & Science Seed FundEmpirical Ventures
PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.
AI & Machine LearningBiotechDeep Tech
Hannah Sore(Founder)in
Co-investorsCambridge Angels groupMartlet CapitalMC Healthcare VenturesDiamond Edge VenturesO2h VenturesParkwalk Advisors
Singular provides a marketing analytics platform that combines cost aggregation, mobile and cross-device attribution, fraud prevention, and creative analytics for marketing teams.
AdTechMarketing TechSaaSSan Francisco, US
Gadi Eliashiv(CEO & Co-founder)inSusan Kuo(COO & Co-founder)inEran Friedman(CTO & Co-founder)inNichael Oiknine(Executive Officer)Stephanie Pilon(CMO)inYoni Amias(CCO)in
Co-investorsMethod CapitalNorwest Venture PartnersTitanium VenturesTransLink CapitalGeneral CatalystZ Venture Capital+3 more
.png)
Singular Photonics develops digital image sensors based on single-photon avalanche diode (SPAD) technology, which convert photons directly into digital signals to capture depth and temporal data as 4D images.
Deep TechHardwareMedical DevicesSemiconductors
Co-investorsCambridge Angels groupQubits VenturesACF InvestorsOld College CapitalScottish Enterprise
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.